Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
memo - Magazine of European Medical Oncology
Published in: memo - Magazine of European Medical Oncology 1/2015

01-04-2015 | short review

PET in lymphoma: who, when, how often, pitfalls?

Author: Christian Uprimny, MD

Published in: memo - Magazine of European Medical Oncology | Issue 1/2015

Login to get access

Abstract

For optimal therapy management in patients with lymphoma, sensitive and specific imaging modalities for accurate initial staging and evaluation of response to therapy are crucial. Fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) that combines metabolic information of 18F-FDG PET with morphological information of diagnostic CT has proven to be a very useful tool in the work-up of lymphomas. Especially in 18F-FDG-avid tumours like Hodgkin lymphoma and high-grade, aggressive non-Hodgkin lymphoma, 18F-FDG PET/CT is widely used for pre-treatment staging and response evaluation after completion of therapy with convincing evidence that it is more accurate than conventional imaging modalities. Although 18F-FDG PET/CT is also applied in other subtypes of lymphoma and in other clinical indications such as early response assessment, its benefit in these settings remains controversial. This review is intended to highlight the accepted clinical applications for 18F-FDG PET/CT in lymphoma, delivering a short clinical guideline when it is recommended to perform 18F-FDG PET/CT in a patient with lymphoma.
Literature
1.
Rodriguez-Vigil B, Gomez-Leon N, Pinilla I, et al. PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT. J Nucl Med. 2006;47(10):1643–8.PubMed
2.
Hutchings M, Loft A, Hansen M, et al. Positron emission tomography with or without computed tomography in the primary staging of Hodgkinʼs lymphoma. Haematologica. 2006;91:482–9.PubMed
3.
Schaefer NG, Hany TF, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging—do we need contrast-enhanced CT? Radiology. 2004;232:823–9.CrossRefPubMed
4.
Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG-PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(3):620–5.CrossRefPubMedCentralPubMed
5.
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579–86.CrossRefPubMed
6.
Pelosi E, Pregno P, Penna D, et al. Role of whole body [18F] fluorodeoxyglucose positron emission tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non-Hodgkin lymphoma. Radiol Med. 2008;113(4):578–90.CrossRefPubMed
7.
Le Dortz L, De Guibert S, Bayat S, et al. Diagnostic and prognostic impact of (18F)F-FDG PET/CT in follicular lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(12):2307–14.CrossRefPubMed
8.
Jerusalem G, Beguin Y, Najjar F, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkinʼs lymphoma (NHL). Ann Oncol. 2001;12(6):825–30.CrossRefPubMed
9.
Bishu S, Quigley J.M., Schmitz J, et al. F-18-fluoro-deoxy-glucose (FDG) positron emission tomography (PET) in the assessment of peripheral T-cell lymphomas. Leuk Lymphoma. 2007;48(8):1531–8.CrossRefPubMed
10.
Kako S, Izutsu K, Ota Y, et al. FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol. 2007;18(10):1685–90.CrossRefPubMed
11.
Hofmann M, Kletter K, Diemling M, et al. Positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) does not visualize extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type. Ann Oncol. 1999;10(10):1185–9.CrossRef
12.
Weiler-Sagie M, Bushelev O, Epelbaum R, et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med. 2010;51(1):25–30.CrossRefPubMed
13.
Isasi CR, Lu P, Blaufox MD. A metaanalysis of 18F-2-deoxy-2-fluouro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer. 2005;104(5):1066–74.CrossRefPubMed
14.
Sasaki M, Kuwabara Y, Koga H, et al. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Ann Nucl Med. 2002;16(5):337–45.CrossRefPubMed
15.
Schoeder H, Meta J, Yap C, et al. Effect of whole body (18)F-FDG PET imaging on clinical staging and management of patients with malignant lymphoma. J Nucl Med. 2001;42(8):1139–43.
16.
Naumann R, Beuthien-Baumann B, Reiss A, et al. Substantial impact of FDG PET imaging on the therapy decision in patients with early-stage Hodgkinʼs lymphoma. Br J Cancer. 2004;90(9):620–5.CrossRefPubMedCentralPubMed
17.
Cheng G, Chen W, Chamroonraat W, et al. Biopsy versus FDG PET/CT in the initial evaluation of bone marrow involvement in pediatric lymphoma patients. Eur J Nucl Med Mol Imaging. 2011;38(8):1469–76.CrossRefPubMed
18.
Schaefer NG, Strobel K, Taverna C, et al. Bone involvement in patients with lymphoma: the role of FDG-PET/CT. Eur J Nucl Med Mol Imaging. 2007;34(1):60–7.CrossRefPubMed
19.
El-Galaly TC, dʼAmore F, Mylam KJ, et al. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma. J Clin Oncol. 2012;30(36):4508–14.CrossRefPubMed
20.
Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014 Aug 11. Epub ahead of print.
21.
Von Treskow B, Plütschow A, Fuchs A, et al. Dose-intensification in early unfavorable Hodgkinʼs lymphoma: final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol. 2012;30(9):907–13.CrossRef
22.
Dunleavy K, Mikhaeel G, Sehn LH, et al. The value of positron emission tomography in prognosis and response assessment in non-Hodgkin lymphoma. Leuk Lymphoma. 2010;51(Suppl. 1):28–33.CrossRefPubMed
23.
Terasawa T, Lau J, Bardet S, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkinʼs lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906–14.CrossRefPubMed
24.
Gallamini A, Rigacci L, Merli F, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkinʼs disease. Haematologica. 2006;91(4):475–81.PubMed
25.
Cerci JJ, Pracchia LF, Linardi CC, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337–43.CrossRefPubMed
26.
Moskowitz AJ, Yahalom J, Zelenetz AD, et al. High-dose chemo-radiotherapy for relapsed or refractory Hodgkin lymphoma and the significance of pre-transplant functional imaging. Br J Haematol. 2010;148(6):890–7.CrossRefPubMedCentralPubMed
27.
Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol. 2007;25(5):571–8.CrossRefPubMed
28.
Juweid ME. 18F-FDG PET as a routine test for post therapy assessment of Hodgkinʼs lymphoma: where is the evidence. J Nucl Med. 2008;49(1):9–12.CrossRefPubMed
29.
Zijlstra JM, Linduer-van der Werf G, Hoekstra OS, et al. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systemic review. Haematologica. 2006;91(4):522–9.PubMed
30.
Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkinʼs disease and non-Hodgkinʼs lymphoma. Br J Haematol. 2001;115(4):793–800.CrossRefPubMed
31.
Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol. 2009;27(11):1781–7.CrossRefPubMed
32.
Crocchiolo R, Fallanca F, Giovacchini G, et al. Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with lymphoma. Ann Hematol. 2009;88(12):1229–36.CrossRefPubMed
Metadata
Title
PET in lymphoma: who, when, how often, pitfalls?
Author
Christian Uprimny, MD
Publication date
01-04-2015
Publisher
Springer Vienna
Published in
memo - Magazine of European Medical Oncology / Issue 1/2015
Print ISSN: 1865-5041
Electronic ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-014-0175-3

Other articles of this Issue 1/2015

memo - Magazine of European Medical Oncology 1/2015 Go to the issue

short review

Optimal follow-up of ovarian cancer patients

review

Predicting drug sensitivity by 3D cell culture models

short review

Optimal follow-up of cervical cancer patients

editorial

Multiple myeloma: the biology, the clinic, and the future

short review

Beyond R-CHOP: treatment of double hit, tripple hit, MYC + NHL?

review

Radiotherapy for brain metastases: are we getting better?
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits